Biotalys and Novonesis have entered into an agreement to advance Evoca NG – the next generation of Biotalys’ product candidate Evoca* – to the final stage of development.

The agreement secures Novonesis as the global manufacturing partner for Evoca NG, leveraging its fermentation capabilities.

Biotalys also grants Novonesis the rights to distribute and sell Evoca NG in select crops outside of the U.S., in exchange for royalty payments. In addition, the companies will explore future collaborations involving Biotalys’ Agrobody technology platform, including potential combinations with Novonesis’ biocontrol technology.

“We are fortunate to have the opportunity to collaborate with (Novonesis) on producing Evoca NG, enabling us to introduce the innovative Agrobody technology to our global customers,” said Kevin Helash, chief executive officer of Biotalys. This is an important step forward for Biotalys as we lay the foundation for future commercial launches from our Agrobody 2.0 technology platform.”

Biotalys’ Evoca NG is a biofungicide candidate with the same active ingredient as the company’s first-generation Evoca, but with an optimized production process and formulation enabling commercialization of the product at competitive levels. Evoca and Evoca NG aim to provide fruit and vegetable growers with an efficacious new crop protection product to help control Botrytis and powdery mildew.

*Evoca: Pending Registration. This product is not currently registered for sale or use in the United States, the European Union, or elsewhere and is not being offered for sale.